NVCR — Novocure Ltd
NASDAQ · Healthcare · Medical Devices
$17.38
-$0.27 (-1.53%)
Novocure Ltd (NVCR) is a medical devices company listed on NASDAQ. It is led by Frank Leonard, based in Neuhofstrasse 21, Baar, Switzerland, 6340, with about 1,605 employees. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Latest reported NVCR revenue for 2025-09-30 was $167.2M. Net income was -$37.3M. Revenue was up 5.3% from 2025-06-30 to 2025-09-30. NVCR currently screens at market cap $1.99B.
Use this NVCR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NVCR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NVCR SEC filings page. Lician reads the product cache first so this HTML stays unique to Novocure Ltd even when a live quote feed is slow.
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCR Key Statistics
Market Cap
$1.99B
Volume
236,709
Previous Close
$17.82
Day Range
$17.39 – $17.97
EPS
-$1.56
Revenue
$605.22M
Net Income
-$168.63M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+18.8%
Profit Margin
-27.9%
Employees
1,605
NVCR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $605.22M | $509.34M | $128.43M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$168.63M | -$207.04M | -$37.30M |
| EPS (Diluted) | -$1.56 | -$1.95 | -$0.36 |
Total Assets
$1.24B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$163.77M
Operating Cash Flow
-$26.37M
Free Cash Flow
$0.00
Novocure Ltd Company Information
- Chief Executive Officer
- Frank Leonard
- Headquarters
- Neuhofstrasse 21, Baar, Switzerland, 6340
- Website
- www.novocure.com
- Phone
- 44 15 3475 6700
- IPO / Founded
- 2015-10-02
- Sector
- Healthcare
- Industry
- Medical Devices